About Blueprint Medicines
Blueprint Medicines is a company based in Cambridge (United States) founded in 2008 was acquired by Sanofi in June 2025. Blueprint Medicines has raised $115 million across 4 funding rounds from investors including Royalty Pharma, Sanofi and TD Securities. The company has 201 employees as of December 31, 2022. Blueprint Medicines has completed 1 acquisition, including Lengo Therapeutics. Blueprint Medicines offers products and services including Avapritinib, Elenestinib, and BLU-808. Blueprint Medicines operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Cambridge, United States
- Employees 201 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Blueprint Medicines Corporation
-
Annual Revenue
$17.31 M (USD)-92as on Dec 31, 2023
-
Net Profit
-$67.09 M (USD)87as on Dec 31, 2024
-
EBITDA
$80.32 M (USD)116as on Dec 31, 2024
-
Total Equity Funding
$115 M (USD)
in 4 rounds
-
Latest Funding Round
$1.25 B (USD), Post-IPO
Jun 30, 2022
-
Investors
Royalty Pharma
& 14 more
-
Employee Count
201
as on Dec 31, 2022
- Investments & Acquisitions
-
Acquired by
Sanofi
(Jun 02, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Blueprint Medicines
Blueprint Medicines offers a comprehensive portfolio of products and services, including Avapritinib, Elenestinib, and BLU-808.
Treats systemic mastocytosis and gastrointestinal stromal tumors.
Targets indolent and advanced systemic mastocytosis.
Addresses chronic urticaria and other mast cell diseases.
People of Blueprint Medicines
Unlock access to complete
Unlock access to complete
Leadership Team
55 people
Operations Team
13 people
Human Resources and Administration
12 people
Software Development Team
12 people
Senior Team
12 people
Sales and Marketing
10 people
Area Team
10 people
Product Management Team
9 people
Unlock access to complete
Funding Insights of Blueprint Medicines
Blueprint Medicines has successfully raised a total of $115M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.25 billion completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Blueprint Medicines
Blueprint Medicines has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Royalty Pharma, Sanofi and TD Securities.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in marketed and late-stage biopharmaceutical companies.
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked |
Investor details for Blueprint Medicines
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Blueprint Medicines
Blueprint Medicines has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Lengo Therapeutics.
Investment portfolio details for Blueprint Medicines
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Precision medicines for oncology are developed using covalent drug-target technology.
|
Locked | Locked | 2020 | Locked |
Complete acquisition details for Blueprint Medicines
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Blueprint Medicines
Detailed financials for Blueprint Medicines
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Blueprint Medicines Comparisons
Peer comparison for Blueprint Medicines
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Blueprint Medicines
Blueprint Medicines operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Blueprint Medicines
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Blueprint Medicines
Complete news archive for Blueprint Medicines
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Blueprint Medicines
Blueprint Medicines was founded in 2008 and raised its 1st funding round 4 years after it was founded.
Blueprint Medicines is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Blueprint Medicines is a funded company, having raised a total of $115M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Blueprint Medicines is 201.
Annual revenue of Blueprint Medicines is $17.31M as on Dec 31, 2023.
Blueprint Medicines was founded in 2008 and is headquartered in Cambridge, United States. Operations focus on the biotechnology sector, where selective kinase inhibitors are developed for patients with genomically defined cancers. The approach involves analysis of genetic drivers in cancer and other kinase-related diseases, supported by a proprietary library of chemical compounds. Targets that are difficult to drug are addressed through this method.
Blueprint Medicines's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Blueprint Medicines offers Avapritinib, Elenestinib, and BLU-808.
Blueprint Medicines has made 1 acquisition, including Lengo Therapeutics.
Blueprint Medicines has 15 investors. Key investors include Royalty Pharma, Sanofi, TD Securities, RA Capital, and Perceptive Advisors.